SCM
ALXN

Segantii Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Segantii Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-771,618
Closed -$142M – 659
2021
Q2 		$142M Buy
771,618
+342,804
+80% +$58.8M 4.07% 2
2021
Q1 		$65.6M Buy
428,814
+319,477
+292% +$49.4M 2.81% 5
2020
Q4 		$17.1M Buy
109,337
+73,187
+202% +$9.4M 0.79% 37
2020
Q3 		$4.14M Buy
36,150
+9,750
+37% +$1.05M 0.32% 35
2020
Q2 		$2.96M Buy
+26,400
New +$2.8M 0.21% 46

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Segantii Capital Management's ALXN Position: Q3 2021 in Review

Segantii Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 771,618 shares — an estimated $142M sold.

Segantii Capital Management first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $142M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Segantii Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Segantii Capital Management sold 771,618 Alexion Pharmaceuticals shares in Q3 2021, an estimated $142M.
  • Segantii Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Segantii Capital Management's Alexion Pharmaceuticals position peaked at $142M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Segantii Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.